Alcalá-Pérez D, Ramos-Garibay JA, Landini-Enríquez VV

Language: Spanish
References: 13
Page: 117-121
PDF size: 2293.86 Kb.

ABSTRACT

Keratoacanthoma is an epidermal keratotic tumor that has a controversial biological behavior, due to its close relationship with cutaneous squamous cell carcinoma. The etiology of keratoacanthoma is multifactorial, it develops from the hair follicle, and it is associated with genetic mutations of the TGF-β receptor. Clinically it courses with three stages: growth, stabilization and involution. By histopathology more aggressive variants have been detected, with perineural invasion, which are not compatible with the hypothesis that it is a benign tumor. In addition, cases with lymph node metastasis have been reported. So, the following question arises: should keratoacanthoma be reclassified, or remain classified within the benign tumors? Nowadays there are no clinical or histological data that allow us to know how a keratoacanthoma will evolve. So, at this point of time, this interesting tumor needs to be forward studied and treated as a malignancy. In this review we summarize the clinical, histological and molecular differences and similarities between keratoacanthoma and squamous cell carcinoma.

REFERENCES

1. Villanueva-Otamendi A, Ramos-Garibay JA, Alcalá-Pérez D, Medina-Bojórquez A, Torres-González S, Enríquez-Merino J. Queratoacantoma: ¿pseudocáncer o carcinoma epidermoide? Dermatología Rev Mex. 2012; 56: 26-29.

2. Savage JA, Maize JC. Keratoacanthoma clinical behavior: a systematic review. Am J Dermatopathol. 2014; 36: 422-429.

3. Watanabe IC, Magalhães RF, de Moraes AM, Stelini RF, Cintra GF, Metze K et al. Keratoacanthoma and keratoacanthoma-like squamous cell carcinoma: similar morphology but different pathogenesis. Medicine (Baltimore). 2015; 94: e934.

4. Lacouture ME, Morris JC, Lawrence DP, Tan AR, Olencki TE, Shapiro GI et al. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol Immunother. 2015; 64: 437-446.

5. Gleich T, Chiticariu E, Huber M, Hohl D. Keratoacanthoma: a distinct entity? Exp Dermatol. 2016; 25: 85-91.

6. Cribier B. Keratoacanthoma? Better to say “squamous cell carcinoma, keratoacanthoma type”. Ann Dermatol Venereol. 2008; 135: 541-546.

7. Zito PM, Scharf R. Keratoacanthoma [Updated 2018 Apr 25]. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499931/

8. Rossi AM, Park B, Qi B, Lee EH, Busam KJ, Nehal KS. Solitary large keratoacanthomas of the head and neck: an observational study. Dermatol Surg. 2017; 43: 810-816.

9. Weedon D. Tumors of the epidermis. In: Houston M, Davie B, Lowsen K, eds. Weedon’s skin pathology. 3rd edition. Elsevier, Churchill Livingstone: 2010. Chapter 31: pp. 682-685.

10. Espinoza D, Mazariegos M, Alvarado J. Queratoacantoma. Rev Fac Cienc Med. 2015; 12: 50-55.

11. Zito G, Saotome I, Liu Z, Ferro EG, Sun TY, Nguyen DX et al. Spontaneous tumour regression in keratoacanthomas is driven by Wnt/retinoic acid signalling cross-talk. Nat Commun. 2014; 5: 3543.

12. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014; 511: 246-250.

13. Ferguson-Smith MA, Goudie DR. Digenic/multilocus aetiology of multiple self-healing squamous epithelioma (Ferguson-Smith disease): TGFBR1 and a second linked locus. Int J Biochem Cell Biol. 2014; 53: 520-525.